MARKET WIREYahoo! Finance Canada • 20h ago
Femasys Inc. (FEMY) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
Why FEMY Stock dropped -3.65% Today — RQD Quant Desk Flash
$1.32 -3.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.31
Femasys Inc. (FEMY) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $11.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on FEMY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is FEMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Femasys Inc. (NASDAQ: FEMY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.32 (-3.65% 1D, market cap $11.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FEMY ranks #812 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does FEMY compare to ICU and PLSM in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), FEMY carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, ICU (SeaStar Medical Holding Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, FEMY leads on earnings multiple (N/A) while FEMY leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for FEMY?
▼
Per FEMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339005), Femasys Inc. generated $2.3M in revenue (+40.8% YoY), -$18.6M in net income, and -$19.2M in free cash flow against $20.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.31 (-0.85%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FEMY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY FEMY SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (20% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 62% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.76-5.1% Next Q
38
Q2 (-2Q)Grade E$1.67-18% Next Q
35
Q3 (-1Q)Grade E$1.37-3.6% Next Q
33
CurrentGrade E$1.32-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a FEMY Turnaround Squeeze
While FEMY currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.22) and Max Pain ($1.39) forces dealer call-delta covering toward $23.31.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $FEMY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FEMY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why FEMY Stock dropped -3.65% Today — RQD Quant Desk Flash
Femasys Inc. (FEMY) dropped -3.65% to $1.32, trading at 2% of its 52-week range ($1.3 – $22.2). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.3 – $22.2) with RSI-14 at 28 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.32 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 62% gross margin and $0 annual free cash flow.
Live FEMY Headlines & Catalysts
MARKET WIRESeeking Alpha • 23h ago
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall CottonSeeking Alpha report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 1d ago
Femasys Stock Price Forecast. Should You Buy FEMY?StockInvest.us report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Femasys Inc. Estimates – NASDAQ:FEMYTradingView report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A fund manager reports a passive 468,750-share stake in Femasys (FEMY).Stock Titan report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
CATALYSTStock Titan • 1d ago
Fertility patients get medication coordination and preferred pricing through a new pharmacy partnershipStock Titan report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Femasys Inc. (FEMY) Slides 12.5% to $1.75 as Shares Press Toward Key Support - Golden Crosshttps://www.siam.in/ report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), ScinaiBenzinga report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 3d ago
Femasys Appoints John Moorhead to Board of DirectorsATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standa
CATALYSTYahoo • 13d ago
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNsFirst in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patientsATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FEMY)
- ✓Walkthrough of FEMY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
FEMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -82.26%⚡ TESTING RESISTANCE
2026-11-03O $1.35H $1.37L $1.32C $1.32VOL 95.1K
RES: $1.94SUP: $1.27SMA50: $2.22SMA200: $6.02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
FEMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +40.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on FEMY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for FEMY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FEMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FEMY)
Health Care Rank #812 of 1016
⚔️ ICU vs FEMY Full Matrix →
1. Head-to-Head Health Care Peer Comparison (FEMY vs. ICU, PLSM, SINT, CNSY)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Femasys Inc. (FEMY) ranks #812 by composite RQD confidence (30/100, grade E) and #880 by equity capitalization ($11.5M). Within this direct 5-issuer industry benchmark cohort, FEMY leads on earnings valuation at N/A trailing P/E, while FEMY leads on capital efficiency and profitability with -35.0% ROIC and 62.0% gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with FEMY at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FEMY
ACTIVE
Femasys Inc. | E | 30/100 | — | 62.0% | -35.0% | -3.65% | $11.5M | Benchmark Subject |
| ICU SeaStar Medical Holding Corporation | E | 31/100 | — | 95.7% | -35.0% | -2.23% | $11.8M | /icu-vs-femy → |
| PLSM Pulsenmore Ltd. | D | 47/100 | — | — | — | -1.87% | $10.9M | /plsm-vs-femy → |
| SINT SiNtx Technologies Inc. | E | 33/100 | — | 45.3% | -35.0% | +0.59% | $12.8M | /sint-vs-femy → |
| CNSY Cerenome Inc. | E | 25/100 | — | — | -35.0% | +0.59% | $12.9M | /cnsy-vs-femy → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001339005In its most recent audited fiscal period (FY2025, filed 2025-12-31), Femasys Inc. (FEMY) reported GAAP revenue of $2.3M (+40.8% vs. FY2024 revenue of $1.6M , and +113.9% cumulative change since FY2023) , GAAP net income of -$18.6M, operating cash flow of -$18.7M, and free cash flow of -$19.2M (+4.9% YoY). On the balance sheet, FEMY closed FY2025 with $20.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.3M | -$18.6M | -$18.7M | -$19.2M | $20.7M | — |
| FY2024 (FY) | 2024-12-31 | $1.6M | -$18.8M | -$19.4M | -$20.2M | $12.4M | — |
| FY2023 (FY) | 2023-12-31 | $1.1M | -$14.2M | -$11.3M | -$11.3M | — | — |
3. FEMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FEMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Femasys Inc. (NASDAQ: FEMY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.32 (-3.65% 1D, market cap $11.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FEMY ranks #812 in composite RQD confidence.
How does FEMY compare to ICU and PLSM in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), FEMY carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, ICU (SeaStar Medical Holding Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, FEMY leads on earnings multiple (N/A) while FEMY leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FEMY?
Per FEMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339005), Femasys Inc. generated $2.3M in revenue (+40.8% YoY), -$18.6M in net income, and -$19.2M in free cash flow against $20.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FEMY trading relative to its 50-day, 200-day, and 52-week technical levels?
FEMY last traded at $1.32 (-3.65% on volume of 129,863 shares), positioning the stock -40.54% below its 50-day simple moving average ($2.22) and -78.07% below its 200-day simple moving average ($6.02). Across its 52-week range of $1.30 to $22.20, FEMY sits at the 0.1% percentile with a 14-day RSI of 28.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.15 to $1.49).
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ SEC XBRL & RQD VERIFIED
FEMY — Femasys Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Femasys Inc. (FEMY) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.32 (-3.65% 1D, market capitalization $11.5M).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 62.0%, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Femasys Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. It operates with a market capitalization of $0.0B, though the market data section reports $11.3M. Per the recent news feed, one catalyst references a new pharmacy partnership offering medication coordination and preferred pricing to fertility patients, which suggests a fertility-focused customer base. Revenue was $2.3M in FY 2025, with a reported gross margin of 62%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Femasys Inc. (FEMY) reported $2.3M in annual revenue (up from $1.6M in FY2024, +40.8% YoY) and -$18.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.1M revenue, -$14.2M net income) through FY2025, FEMY scaled operating cash flow to -$18.7M and free cash flow to -$19.2M, backed by $20.7M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.30 – $22.20 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream suppliers and downstream customers are — Sector correlations beyond the Health Care and Medical/Dental Instruments classification are — Investors should note that the absence of mapped links means no second-order ripples can be traced from this source, and that the company's own catalyst set (fertility-focused pharmacy partnership and sales-force execution) would be the primary channel through which operational changes propagate.
- Key Question #1: Can FEMY sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $2.3M and free cash flow of -$19.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is FEMY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
FEMY Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Femasys Inc. (FEMY) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 20h ago
Femasys Inc. (FEMY) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 23h ago
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton Seeking Alpha report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 1d ago
Femasys Stock Price Forecast. Should You Buy FEMY? StockInvest.us report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Femasys Inc. Estimates – NASDAQ:FEMY TradingView report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A fund manager reports a passive 468,750-share stake in Femasys (FEMY). Stock Titan report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stock Titan • 1d ago
Fertility patients get medication coordination and preferred pricing through a new pharmacy partnership Stock Titan report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Femasys Inc. (FEMY) Slides 12.5% to $1.75 as Shares Press Toward Key Support - Golden Cross https://www.siam.in/ report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), Scinai Benzinga report covering Femasys Inc. (FEMY) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
FEMY Bull vs. Bear Conversation Board — What's Your Call at $1.32?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FEMY 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $1.74 (+27.0%)
📌 Pinned Debate Cash rose to $9.3M in FY 2025 from $3.5M in FY 2024 while revenue grew from $1.1M in FY 2023 to $2.3M in FY 2025, and the forensic bala
Cash rose to $9.3M in FY 2025 from $3.5M in FY 2024 while revenue grew from $1.1M in FY 2023 to $2.3M in FY 2025, and the forensic balance sheet pillar scored 10/20 with Altman Z of 2.5.. When you look under the hood at FEMY, Fundamental Cash Engine is 6/20 with 62.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $22.20. My 12M target is $1.74.
VolSurface_Trader 🐂 BULL
@RedlineAuditor Shorting a 3/20 institutional whale-flow stock at $1.37 is dangerous when funds are rotating into Health Care.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $1.10 (-19.7%)
Spot @ $1.37 FCF was -$19.2M in FY 2025, ROIC is -35%, and the RQD rating is 30 with an E grade labeled Strong Sell — Forensic Risk / Avoid.
Careful chasing FEMY at $1.37. FCF was -$19.2M in FY 2025, ROIC is -35%, and the RQD rating is 30 with an E grade labeled Strong Sell — Forensic Risk / Avoid.. Gross margin is 62.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.10 on multiple compression.